Insider filing · ALNY
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
profile →
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare · 57 filings in 24 months
ticker →
Kevin Joseph Fitzgerald sold $583K of Alnylam Pharmaceuticals (ALNY)
Executed Mar 2, disclosed Mar 4, 2 days later.
Value, as filed
$583K
1,802 sh across 4 lots
Executed
Mar 2
the trade date, as filed
Disclosed
Mar 4
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
KFKevin Joseph Fitzgerald (CSO & EVP, Head of Research) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $5.4M of ALNY (11,903 sh across 9 lots, as filed), executed Nov 17 2025.
The name
ALNYHealthcare · Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Kevin Joseph Fitzgerald in ALNY
ALNYSALE
Alnylam Pharmaceuticals, Inc.
$1.3M4,000 sh across 2 lots
Exec Feb 13
Filed Feb 17 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $730K
1,971 sh across 4 lots
Exec Jan 13
Filed Jan 14 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $5.4M
11,903 sh across 9 lots
Exec Nov 17 2025
Filed Nov 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $702K
1,553 sh across 4 lots
Exec Oct 2 2025
Filed Oct 3 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $505K
1,113 sh across 3 lots
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $232K
952 sh across 2 lots
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $272K
1,086 sh × $250.21
Exec Feb 18 2025
Filed Feb 18 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $422K
1,677 sh across 2 lots
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET